Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Selective histocompatibility leukocyte antigen (HLA)-A2 loss caused by aberrant pre-mRNA splicing in 624MEL28 melanoma cells.

The Journal of experimental medicine - 19 Jul 1999

Wang Z, Marincola F M, Rivoltini L, Parmiani G, Ferrone S

Abstract excerpt

Histocompatibility leukocyte antigen (HLA)-A2 is used as a restricting element to present several melanoma-associated antigen (MAA)-derived peptides to cytotoxic T lymphocytes (CTLs). HLA-A2 antigen is selectively lost in primary melanoma lesions and more frequently in metastases. Only scanty information is available about the molecular mechanisms underlying this abnormality, in spite of its potentially negative...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alternative Splicing
Share to DNA, Neoplasm

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Genes, MHC Class I

Share to HLA-A2 Antigen

Share to Immunotherapy

Share to Melanoma

Share to RNA, Neoplasm

Share to RNA Precursors

Source

Open in PubMed Open full text

Identifiers

PMID: 10432284
DOI: 10.1084/jem.190.2.205
PMCID: PMC2195569

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Selective histocompatibility leukocyte antigen (HLA)-A2 loss caused by aberrant pre-mRNA splicing in 624MEL28 melanoma cells.PMID 10432284Read ↗

Loss of single HLA class I allospecificities in melanoma cells due to selective genomic abbreviations.Semantic proximity Read ↗

Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage.Semantic proximity Read ↗

Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway.Semantic proximity Read ↗

beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma.Semantic proximity Read ↗

Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma.Semantic proximity Read ↗

In vivo and in vitro generation of a new altered HLA phenotype in melanoma-tumour-cell variants expressing a single HLA-class-I allele.Semantic proximity Read ↗

Loss of HLA haplotype and B locus down-regulation in melanoma cell lines.Semantic proximity Read ↗

Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes.Semantic proximity Read ↗

Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an in vitro melanoma model.Semantic proximity Read ↗

A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma.Semantic proximity Read ↗

Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy.Semantic proximity Read ↗

A cluster of mutations in HLA-A2 alpha 2 helix abolishes peptide recognition by T cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.